Premarket Biotech Digest – BDX Finalizes Acquisition Deal, VNLPF Receives CRL, EYEG Files S-1

Johnson & Johnson announced results from a Phase 2 clinical trial assessing the triple combination ofOlysio (simeprevir), C.R. Bard Inc. and Becton Dickinson finalize the deal for buying Bard.